Home Uncategorized

Uncategorized

Expanding ketamine’s horizons for rare neurological disorders

William Leonard Pickard participating in celebration for Sasha Shulgin’s new book ‘The Nature of Drugs’

Tryp Therapeutics Partners with Clinlogix for Clinical Trial Support

Henrik Dahl’s Review of Pickard’s ‘The Rose of Paracelsus: On Secrets and Sacraments’

MindMed Closes Upsized Financing of CAD $92.1m (USD $72.7m) to Meet High Investor Demand

MindMed Files Final Prospectus In Connection With Bought Deal Equity Financing

MindMed Files Preliminary Prospectus In Connection With Bought Deal Equity Financing

MindMed Upsizes Previously Announced Bought Deal Public Offering

MindMed Announces $50 Million Bought Deal Public Offering

MindMed Announces Successful Completion of Pre-IND Meeting with the FDA for...

MindMed Streamlines Leadership with Further Emphasis on Integrating Psychedelic Drug Development...

MindMed Announces the Start of the First-Ever Clinical Trial Combining MDMA...

MindMed Adds Chief Development Officer with FDA Phase 2 Psilocybin Clinical...

MindMed Expands Psychedelic Microdosing Division, Adds Groundbreaking Study Evaluating LSD Microdosing...

The Backyard Psychedelic Renaissance: How Bottom-Up Change Is Delivering Psychedelic Access

Dreamshadow Transpersonal Breathwork

Statement Regarding The Church of the Sacred Synthesis

How to Get DMT: Obtaining the Spirit Molecule

Having Sex on DMT: What You Need to Know

DMT Pricing Guide

ABOUT US

PsyNews.com has a single-sector focus. We are a news platform dedicated to covering the psychedelic industry. This includes companies, startups, venture capital firms, investment banks, pharma, research, etc, anything associated with the new emerging industry and asset class. Many of the chemicals and compounds involved are LSD, psilocybin, DMT, ketamine, MDMA, ecstasy, ibogaine, analogs, derivatives, psychedelic mushrooms, fungi, psilocin, entheogens, empathogens, indocybin, magic truffles (psilocybin sclerotia), etc. They range from classical and standard to new and exotic. PsyNews.com will cover all psychedelic news in the psy industry, including current events, updates, and what’s happening everywhere in the sector in term of developments and investments. We will be tracking companies worth, valuation, ROI, financials, stock, revenue, IPO’s, and more. Along with medical, recreational, clinical trials, FDA, mindfulness, psy space, 5-HT2A receptor experiments, and so forth. Join us on an unforgettable journey to the center of the psychedelic industry.